Bile secretory function in the obese Zucker rat: evidence of cholestasis and altered canalicular transport function


Background: Obese Zucker rats (ZR) have been used as an experimental model for non-alcoholic fatty liver disease and are particularly susceptible to various types of liver injury. Bile secretory function has not been assessed in ZR.

Aim: To study bile secretion and expression of the main hepatobiliary transporters in ZR.

Methods: Bile flow and biliary secretion of lipids and glutathione were determined in eight and 14 week old obese ZR and their lean controls. Protein mass and mRNA of the Na+/taurocholate cotransporting polypeptide (Ntcp), the bile salt export pump (Bsep), and the multidrug resistant associated protein 2 (Mrp2) were assessed by western and northern blot, respectively. The effects of administration of a tumour necrosis factor α inactivator (etanercept) and an insulin sensitiser (rosiglitazone) were assessed in obese ZR while leptin was given to non-obese rats to study its effect on Mrp2 expression.

Results: ZR exhibited increased body weight and hyperlipidaemia. Only 14 week old obese ZR has fatty liver. Decreased bile flow and biliary lipid and glutathione secretion as well as reduced hepatic transport of both taurocholate and bromosulphthalein were found in obese ZR. Hepatic Mrp2 protein mass was markedly reduced (~70%) in obese rats while Ntcp and Bsep protein levels were similar to lean rats. Downregulation of Mrp2 seems to involve both transcriptional and post-transcriptional mechanisms probably related to insulin and leptin resistance.

Conclusions: Obese ZR exhibit an impaired bile secretory function with significant functional and molecular alterations consistent with mild cholestasis. A defective hepatobiliary transport capacity may be a contributory factor in rendering the obese ZR more susceptible to liver injury.

Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognised clinicopathological condition that comprises a wide spectrum of liver damage ranging from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis. The underlying mechanisms involved in the transition from uncomplicated steatosis to more advanced stages of the disease are not fully understood. Data gathered from both humans and experimental animals suggest that fatty livers are more prone to a variety of insults such as endotoxin and ischaemia/reperfusion (I/R). The observed increased susceptibility to injury gains importance when an hepatic injury occurs in a fatty liver as it may be followed by an exaggerated hepatocyte necrosis and apoptosis and subsequently by an inflammatory process which in turn may trigger a fibrogenic response resulting in significant collagen deposition.

Animal studies showing increased susceptibility or decreased tolerance of steatotic livers to injury have been conducted mainly in genetically obese rodents such as the ob/ob mice or the obese Zucker rat (ZR). These rodents have defective brain leptin dependent signal transduction due to either lack of leptin production or a dysfunctional leptin receptor, resulting in markedly increased food intake and decreased energy expenditure, which are associated with obesity, insulin resistance, and fatty liver. Both ob/ob mice and obese ZR displayed increased hepatotoxicity and decreased survival after exposure to endotoxin and had increased hepatic injury and decreased survival after 60 minutes of ischaemia compared with lean littermates. However, the specific underlying mechanisms explaining the observed increased sensitivity to liver injury observed in these experimental models of NAFLD are not well known.

Several studies have provided evidence of altered Kupffer cell function and increased hepatocyte sensitivity to tumour necrosis factor α (TNF-α) as relevant phenomena in obesity related liver sensitivity to endotoxin. Additionally, increased lipid peroxidation, neutrophil infiltration, and increased release of TNF-α as well as microcirculatory alterations may also be responsible for the higher rate of dysfunction after I/R in fatty livers.

Bile secretion from the liver has a pivotal physiological role as an excretory route for endo- and xenobiotics. During bile secretory failure or cholestasis, substances normally secreted into bile accumulate inside the cell promoting liver injury and leading to both necrosis and apoptosis. In recent years, the molecular mechanisms of bile formation as well as adaptive changes occurring during cholestasis have been well characterised. The concept that malfunction of hepatobiliary transport proteins is associated with cholestasis and liver injury is now established due to identification of a number of inherited diseases, which are caused by mutations in hepatic solute pumps. As bile secretory function has not been studied in detail in genetically obese animals and disturbed bile formation may be a contributory factor in rendering the fatty liver more susceptible to injury, the present study was conducted mainly in genetically obese rodents such as the ob/ob mice or the obese Zucker rat (ZR). These rodents have defective brain leptin dependent signal transduction due to either lack of leptin production or a dysfunctional leptin receptor, resulting in markedly increased food intake and decreased energy expenditure, which are associated with obesity, insulin resistance, and fatty liver.
carried out to assess bile secretory function in the obese ZR as well as expression of major hepatobiliary transporter proteins of the liver in these animals. Our results show that the obese ZR have significant functional alterations of bile secretory function, consistent with the presence of cholestasis, and exhibit decreased expression and/or function of some critical canalicular transporters resulting in impaired excretory function of the liver.

**EXPERIMENTAL PROCEDURES**

**Animals**

Male lean (?/fa) and obese (fa/fa) ZR (Charles River Laboratories, Wilmington, Massachusetts, USA) of eight and 14 weeks of age were housed in transparent polycarbonate cages and subjected to 12 hour light/darkness cycles at a temperature of 21°C and a relative humidity of 50% throughout the accommodation (at least one week) period. Unless otherwise stated, all animals had free access to standard rodent chow and tap water. Animal experiments were approved by the local ethics review committee on animal experiments according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23, revised 1985). Animals were anaesthetised with a single dose of sodium pentobarbitial (50 mg/kg body weight intraperitoneally) and bile collection was carried out after cannulation of the proximal common bile duct with a PE-10 polyethylene tube just proximal to the bifurcation. Subsequently, livers were removed after a short perfusion with saline solution.

**Analytical procedures**

Bile flow was measured gravimetrically and total biliary bile salts (BS) were quantitated by the 3-alpha-hydroxysteroid-dehydrogenase method. Total biliary phospholipids and biliary cholesterol were measured by standard methods. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total BS were measured using a Merck Diagnostic Kit (E Merck, Darmstadt, Germany). Serum triglycerides, glucose, and cholesterol were measured using the Renaissance kit (New England Nuclear, Boston, Massachusetts, USA). alkaline phosphatase was measured by conventional techniques. Glutathione in liver and bile was determined as described by Anderson and colleagues using the haematoxylin-eosin stain. Serum alkaline phosphatase was measured by conventional techniques. Glutathione in liver and bile was determined as described by Anderson and colleagues using the haematoxylin-eosin stain.

**Expression of hepatic transporter proteins**

Protein mass of hepatic transporters in liver tissue from lean and obese rats was measured as previously described using membrane rich fractions to assess protein expression of the protein levels of the basolateral Mrp homologue Mrp3. In addition, we measured pump (Bsep, Abcb11), and the canalicular export pump for polypeptide (Ntcp, Slc10a1), the canalicular bile salt export against the C terminus 12 amino acid sequence, and a polyclonal rabbit anti-Mrp3 (kindly provided by Carol Soroka, PhD). Immunoreactive bands were quantified by laser densitometry.

To determine Ntcp, Bsep, and Mrp2 mRNA levels, total RNA was isolated from whole liver tissue by acid guanidinium thiocyanate-phenol chloroform extraction. Poly(A) RNA was isolated using oligo(dT)12 linked to magnetic streptavidin beads with the PolyATract mRNA Isolation System IV (Promega, Madison, Wisconsin, USA). Northern blots were performed as previously described. Expression levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as a control as this gene is known to be upregulated in obese ZR. Differences in loading were corrected after reprobing the stripped blots for the “housekeeping” gene cyclophilin. The following cDNA probes were used in the northern blotting analysis: (1) Ntcp: 0.9 kb EcoRI fragment (Genbank M77479) isolated from the full length cDNA cloned into pBluescript; (2) Bsep: 4.0 kb Xho I fragment (Genbank U69487) isolated from the full length cDNA cloned into pcDNA3; (3) Mrp2: 2.5 kb fragment encoding the C terminal half of cDNA (Genbank L49379) amplified by polymerase chain reaction (PCR) and cloned into pCR2.1; (4) GAPDH: a 1.3 kb Pst I fragment isolated from full length cDNA cloned into pGEM3 (Promega Corporation); and (5) cyclophilin: a 1.3 kb rat cyclophilin cDNA obtained by digestion with Pst I of pGEM3 plasmid, as described previously. All amplified reverse transcription-PCR products were verified by sequencing (automated fluorescent sequencing) and BLAST analysis against the Genbank database.

**Transport studies and tissue immunofluorescence**

The function of the canalicular transporters of both BS (Bsep) and organic anions (Mrp2), which are largely responsible for the generation of bile flow, was studied by determining the maximum secretory rate (SRm) of sodium taurocholate (TC) and bromosulphthalein (BSP) using previously described protocols. In addition, qualitative distribution of both Bsep and Mrp2 was assessed using indirect immunofluorescence, as described previously. Digital images were recorded and processed using Adobe Photoshop (Adobe Systems Inc., San Jose, California, USA).

**Pharmacological treatments**

Etanercept, a TNF-α binding moiety derived from soluble TNF-α receptor subunits (Embrel; Wyeth Pharmaceuticals, Madison, New Jersey, USA) was given to obese ZR to study the effects of neutralisation of this inflammatory cytokine on bile secretory function using the protocol described by Geier and colleagues. The effects of reduction of insulin resistance in obese animals was studied after administration of the proliferator activated receptor γ (PPAR-γ) agonist rosiglitazone (3 mg/kg/day orally over seven days), as described previously.

Finally, in order to assess the effects of leptin on bile secretory function and protein mass of canalicular bile salt and organic anion transporters, we carried out experiments involving induction of moderate hyperleptinaemia in 14 week old non-obese animals, as described by Barazzoni and colleagues. Animals underwent either leptin (Research Diagnostics Inc, New Jersey, USA) (n = 3, rate of infusion 0.4 mg/kg/day) or vehicle (n = 3, 5 mmol/l sodium citrate, pH 7.4) infusion via osmotic minipumps implanted subcutaneously in the back (ALZET 2ML1; Alzet Corporation, Palo Alto, California, USA). Vehicle infusion animals were pair fed to leptin treated animals.

**Statistics**

All results are expressed as mean (SEM). A two tailed non-paired Student’s t test was used to compare differences.
between groups. Values were considered significantly different when the p value was equal to or less than 0.05.

RESULTS

Body and liver weight, serum biochemistry, and liver histology

As expected, both eight and 14 week old male obese rats had significantly greater body weights, serum glucose concentrations, and serum lipid levels than their lean male littermates (table 1). Serum BS levels were found to be elevated in 14 week old animals (7.5 (0.96) vs 15.8 (2.7) mmol/l in control and obese animals, respectively) while no differences were found in serum alkaline phosphatase levels. Total liver weights of obese rats were greater than those of lean controls. When liver weight was normalised to body weight, the ratio was reduced in eight week old obese ZR and comparable with lean rats in 14 week old obese ZR. This correlates with the absence of significant hepatic steatosis on histological examination in younger obese animals (fig 1) who do not have a fully developed metabolic syndrome and display mainly peripheral obesity. In the case of 14 week old obese ZR, livers exhibited significant steatosis (>20% of hepatocytes) without significant inflammation. Finally, serum AST levels were significantly increased in obese ZR compared with their lean littermates at both age points studied while no changes were observed in serum levels of either total bilirubin or ALT.

Assessment of bile secretory function

Table 2 shows values obtained after determination of bile flow, bile salt secretion, biliary lipid (cholesterol and phospholipid), and glutathione secretion as well as hepatic glutathione content and SRm of TC and BSP in both eight week and 14 week old obese and lean ZR. An impaired bile secretory function was found in obese ZR at both time points studied, which was mainly characterised by a significant reduction in bile flow by 45–55%, indicating the presence of cholestasis. In contrast, while biliary lipid secretion, biliary

---

### Table 1 Body weight, liver weight, and plasma parameters of lean and obese Zucker rats

<table>
<thead>
<tr>
<th></th>
<th>8 week old ZR</th>
<th>14 week old ZR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lean (/?fa)</td>
<td>Obese (fa/fa)</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>198 (7.4)</td>
<td>251 (7.9)*</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>6.2 (0.21)</td>
<td>9.4 (0.36)*</td>
</tr>
<tr>
<td>Body/liver weight</td>
<td>32.1 (0.7)</td>
<td>26.8 (0.76)*</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>132.9 (6.5)</td>
<td>151.2 (9.1)*</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>84.8 (4.3)</td>
<td>193.4 (19.4)*</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>46.9 (4.9)</td>
<td>58.0 (0.2)</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>72.1 (2.6)</td>
<td>123.9 (32.2)*</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>33.7 (2.9)</td>
<td>293.8 (59)*</td>
</tr>
<tr>
<td>Bilirubin (?mol/l)</td>
<td>9.0 (1.0)</td>
<td>10.9 (1.3)</td>
</tr>
</tbody>
</table>

Data represent mean (SD), n=3–12 per group. ZR, Zucker rat; AST, aspartate aminotransferase; ALT, alanine aminotransferase. *p<0.05 compared with respective lean control.
glutathione secretion, and maximum transport of TC and BSP were reduced in both eight and 14 week old obese ZR, basal biliary secretion of BS was significantly reduced only in eight week old animals. In addition, hepatic glutathione content and γ-glutamylcysteine synthetase activity (data not shown) were similar in ZR and lean controls at both ages studied, suggesting that reduced biliary glutathione excretion is probably due to a defect in canalicular transport of this tripeptide.

**Protein expression levels of hepatobiliary transporters**

Immunoblotting was performed on liver membrane fractions from obese ZR and their lean littersmates at eight and 14 weeks of age to determine if the impaired bile secretory function observed in obese rats correlated with changes in protein mass of the major hepatobiliary transporters. While no changes were observed in the protein mass of Ntcp, the main sinusoidal bile acid importer of the hepatocyte (data not shown), obese ZR had significantly reduced Mrp2 protein levels at both time points studied (fig 2). Obese ZR had an 80% and 60% reduction in Mrp2 protein mass at eight and 14 weeks old, respectively. On the other hand, Bsep protein levels were similar in lean and obese ZR. Finally, Mrp3 protein levels, which generally increase when Mrp2 levels are reduced, remained unchanged, indicating that decreased Mrp2 expression is not necessarily accompanied by increased Mrp3 expression, as reported by Cao and colleagues.

**mRNA expression levels of hepatic transporters**

Steady state mRNA levels of canalicular transporters were quantified using northern blot analysis. As shown in fig 3, a significant decrease in expression of both Mrp2 and Bsep mRNA levels was observed, being more prominent at 14 weeks of age. Mrp2 levels at eight weeks of age were not significantly decreased compared with lean controls while there was a 64% decrease at 14 weeks of age. mRNA levels for Bsep were decreased at both eight and 14 weeks of age by 46% and 53%, respectively. Consistent with previous reports we observed increased expression of GAPDH mRNA levels in obese ZR even though the difference was statistically significant only at 14 weeks of age.

**Bsep and Mrp2 tissue immunofluorescence**

To assess qualitative distribution of the main canalicular transporters Bsep and Mrp2, we performed indirect immunofluorescence in 14 week old obese ZR and their lean littersmates. Figure 4 shows representative images of immunostaining of Mrp2, which was downregulated in obese ZR, demonstrating decreased labelling of the canalicular membrane in livers from obese rats. Bsep labelling (not shown) remained unchanged.

**Assessment of potential mechanisms of Mrp2 downregulation in obese Zucker rats**

In attempting to address the underlying mechanism of the observed downregulation of the xenobiotic transporter Mrp2 in ZR, we conducted experiments involving neutralisation of

---

**Table 2** Bile flow, biliary secretion of biliary lipids and glutathione, hepatic glutathione content, and maximal bromosulphthalein transport in lean and obese Zucker rats

<table>
<thead>
<tr>
<th></th>
<th>8 week old ZR</th>
<th>14 week old ZR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lean (fa/fa)</td>
<td>Obese (fa/fa)</td>
</tr>
<tr>
<td>Bile flow (µl/min × g liver)</td>
<td>2.9 (0.2)</td>
<td>1.6 (0.2)*</td>
</tr>
<tr>
<td>Glutathione (mmol/min × g liver)</td>
<td>5.5 (0.7)</td>
<td>1.1 (0.5)*</td>
</tr>
<tr>
<td>Cholesterol (mmol/min × g liver)</td>
<td>43 (0.8)</td>
<td>1.0 (0.13)*</td>
</tr>
<tr>
<td>Phospholipids (mmol/min × g liver)</td>
<td>40 (0.6)</td>
<td>1.4 (0.3)*</td>
</tr>
<tr>
<td>Liver glutathione (nmol/mg liver)</td>
<td>3.9 (0.5)</td>
<td>4.3 (0.26)</td>
</tr>
<tr>
<td>BSP SRm (nm/min × g liver)</td>
<td>390 (32)</td>
<td>274 (26.9)*</td>
</tr>
<tr>
<td>Mrp3 expression (µg/mg liver)</td>
<td>297 (1.1)</td>
<td>18.8 (3.2)*</td>
</tr>
</tbody>
</table>

Data represent mean (SEM), n=4-6 per group.

ZR, Zucker rat; SRm, maximal secretory rate; TC, taurocholate; BSP, bromosulphthalein.

*p<0.05 compared with respective lean control.

---

**Figure 2** Protein expression of hepatic transporters in eight and 14 week old lean and obese Zucker rats (ZR). (A) Multidrug resistant associated protein 2 (Mrp2), bile salt export pump (Bsep), and multidrug resistant associated protein 3 (Mrp3) protein levels in plasma membrane fractions of lean and obese ZR livers. Approximately 50 μg of membrane proteins were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Immunoblotting was performed and bound antibodies were visualised as described in materials and methods. Each band represents the results of a single animal. Transport proteins are indicated on the left of each blot and animal groups at the top. Representative experiments with four rats per group are shown. β-Actin protein mass was used as a loading control. (B) Bar diagram showing western blot band volume as per cent of control for Mrp2, Bsep, and Mrp3. *p<0.05.
the inflammatory cytokine TNF-α in obese rats using the anti-TNF-α inhibitor etanercept, reduction of insulin resistance by treating obese ZR with the PPAR-γ agonist rosiglitazone, and induction of hyperleptinaemia in non-obese animals. After administration of etanercept we did not find any significant changes in bile secretory function parameters (bile flow, bile salt secretion, or glutathione secretion; data not shown) or Mrp2 protein levels in etanercept treated rats compared with non-treated obese ZR (fig 5). On the other hand and in agreement with previous reports,37 treatment of obese ZR with rosiglitazone reversed some features of insulin resistance, such as hyperlipidaemia and fatty liver (data not shown), and significantly increased Mrp2 protein mass by twofold (fig 6) with only partial restorations of biliary transport abnormalities (data not shown). Finally, treatment of non-obese rats with recombinant leptin for one week induced a significant threefold increase in protein mass of Mrp2 (fig 6). Thus it seems likely that insulin and particularly leptin resistance are involved in the observed downregulation of Mrp2 in obese ZR.

DISCUSSION

The present study found evidence of mild cholestasis in obese ZR, supported by significantly reduced bile flow and elevated serum BS levels, which is consistent with this pathophysiological condition.44 Basal and stimulated BS secretion, biliary secretion of cholesterol, phospholipids, and glutathione, as well as SRm of BSP were found to be reduced in both eight and 14 week old obese ZR. Collectively, these results suggest that obese ZR have a reduced canalicular transport capacity for both BS and non-BS biliary constituents. Reduction in bile flow is mainly due to a decrease in the bile acid independent fraction and most probably related to the marked decrease in biliary glutathione secretion into bile as this tripeptide is considered the major driving force for bile acid independent flow.44

Assessment of expression of several hepatic transporters responsible for the generation of bile flow, which are critical for biliary extrusion of BS and organic anions, showed that Mrp2 is markedly reduced in obese ZR. Eighty and 60% decreases in Mrp2 protein content of isolated liver plasma membrane fractions were observed in eight and 14 week old obese animals, respectively. Mrp2 downregulation appeared to involve both transcriptional and post-transcriptional events, because no changes in mrp2 mRNA levels were detected by northern blot analysis in eight week old animals but a significant decrease in Mrp2 message was seen in older animals (fig 3). Decreased Mrp2 protein levels correlated

Figure 3  Decreased expression of hepatic canalicular transporter mRNA levels in eight and 14 week old Zucker rats (ZR). (A) Multidrug resistant associated protein 2 (mrp2), bile salt export pump (Bsep), and glyceraldehyde-3-phosphate dehydrogenase (gapdh) mRNA expression in lean and obese ZR. Total RNA was isolated from lean and obese animals and 5 μg polyA+RNA from each sample was fractionated on 1% formaldehyde-agarose probed with cDNAs for the various genes, as described in materials and methods. Each band represents the results of a single animal. Gene names are indicated on the left of each gel and animal groups at the top. (B) Bar diagram showing relative mRNA expression levels of mrp2, Bsep, and gapdh normalised to cyclophilin expression. *p<0.05 compared with controls.

Figure 4  Indirect immunofluorescent localisation of multidrug resistant associated protein 2 (Mrp2) in 14 week old control and obese Zucker rats (ZR). Frozen liver sections from control (A) and obese (B) ZR were used to assess qualitative distribution of Mrp2 by indirect immunofluorescence, as described in material and methods. Decreased labelling of canalicular membranes was observed accounting for reduction in Mrp2 protein expression in obese ZR.
Induced by endotoxin are strikingly similar to those seen in mediated by Mrp2. Thus it is highly likely that the and reduced biliary secretion of glutathione, which is observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.

In addition to Mrp2 downregulation, functional impairment of Bsep is suggested by our results. Decreased basal and maximum biliary bile salt secretion was seen in obese animals in spite of similar protein expression levels as those seen in control animals. Although the underlying mechanisms of this alteration remain to be elucidated, it is highly likely that the observed reduction in Mrp2 was responsible for the reduction in bile salt independent bile formation. Additionally, normal hepatic content and synthesis of glutathione in obese ZR (data not shown) also suggest a primary biliary transport defect of this tripeptide into bile.
In summary, the present study shows that ZR exhibit impaired bile secretory function with early cholestatic changes even before the occurrence of fatty liver. Significant molecular alterations were observed in the liver of obese rats, including marked downregulation of Mrp2. These functional and molecular changes suggest the existence of a reduced hepatic ability to excrete endo- and xenobiotics in the obese ZR. We postulate that a defective hepatobiliary transport capacity may be a contributory factor in rendering ZR more susceptible to liver injury. Further studies will be carried out in our laboratory to confirm this hypothesis. If this is the case, cholestasis could be a further mechanism whereby hepatocytes laden with fat are sensitised to the development of necrosis or apoptosis when subjected to stress.

ACKNOWLEDGEMENTS

This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología a (FONDECYT no.1020641 to MA and no.1005063 to LA) and from NIH (HD20632 to FJS). Anti-rat Bsep antibody was kindly provided by Dr Bruno Stieger (Zurich, Switzerland) and anti-rat Mrp2 antibody was a generous gift from Dr Dietrich Keppler (Heidelberg, Germany). Anti-rat Mrp3 was provided by Dr Carol Soroka (New Haven, Connecticut, USA).

Authors’ affiliations

M Pizarro, N Salis, JF Miquel, L Accatino, M Arrese, Department of Gastroenterology, School of Medicine, Catholic University of Chile, Santiago, Chile

N Balasubramaniyan, FJ Suchy, M Ananthanarayanan, Laboratory of Developmental and Molecular Hepatology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY, USA

A Solar, I Duarte, Department of Pathology, School of Medicine, Catholic University of Chile, Santiago, Chile

M Trauner, Division of Gastroenterology, Department of Internal Medicine, University Hospital, Graz, Austria

REFERENCES

1 Alba LM, Lindor K. Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2003;17:977–86.


3 Sanyol AJ. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 2003;124:1461–92.


